at://
/
app.bsky.feed.post
/
3mf5ofzgn2224
sign in
All
4
Record
2
Post
1
PostEmbed
1
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
Also worth considering: are we even measuring the right mechanism? Some mAbs may derive clinical activity from Fc-mediated effects (as seen with CTLA-4), not just target blockade. Nice perspective here: ascopubs.org/doi/10.1200/...
4mo
ascopubs.org
Is Unmutated IgG1 a Wrong Choice for Therapeutic Antibodies Targeting Immune Checkpoints? Lessons From the Clinical Failures of the First Anti–TIGIT Antibodies
Yago Garitaonaindia MD
